Heron Therapeutics (HRTX) Receives News Sentiment Score of -0.03

Media coverage about Heron Therapeutics (NASDAQ:HRTX) has been trending somewhat negative on Thursday, according to AlphaOne Sentiment Analysis. The research firm, a subsidiary of Accern, identifies negative and positive media coverage by analyzing more than 20 million blog and news sources. AlphaOne ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Heron Therapeutics earned a media sentiment score of -0.03 on AlphaOne’s scale. AlphaOne also gave news headlines about the biotechnology company an impact score of 32 out of 100, meaning that recent media coverage is unlikely to have an effect on the company’s share price in the next several days.

These are some of the news articles that may have effected AlphaOne Sentiment Analysis’s scoring:

Heron Therapeutics (NASDAQ:HRTX) traded up 1.95% during midday trading on Thursday, hitting $15.70. The stock had a trading volume of 336,362 shares. Heron Therapeutics has a 52 week low of $12.21 and a 52 week high of $24.00. The company’s 50 day moving average price is $14.47 and its 200-day moving average price is $14.74.

Heron Therapeutics (NASDAQ:HRTX) last issued its quarterly earnings data on Thursday, February 23rd. The biotechnology company reported ($1.22) EPS for the quarter, missing analysts’ consensus estimates of ($1.17) by $0.05. The business earned $1.28 million during the quarter, compared to analysts’ expectations of $1.07 million. Equities analysts expect that Heron Therapeutics will post ($3.49) EPS for the current fiscal year.

A number of equities research analysts have recently commented on HRTX shares. Leerink Swann set a $21.00 price target on Heron Therapeutics and gave the stock a “buy” rating in a research report on Thursday, January 5th. Jefferies Group LLC set a $29.00 price target on Heron Therapeutics and gave the stock a “buy” rating in a research report on Thursday, January 5th. Cowen and Company reaffirmed a “buy” rating and set a $40.00 price target on shares of Heron Therapeutics in a research report on Friday, January 6th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $34.00 price target on shares of Heron Therapeutics in a research report on Friday, January 6th. Finally, Zacks Investment Research lowered Heron Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, January 10th. One research analyst has rated the stock with a hold rating and ten have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $36.22.

TRADEMARK VIOLATION NOTICE: This piece of content was published by WKRB News and is the property of of WKRB News. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of United States and international copyright law. The correct version of this piece of content can be read at http://www.wkrb13.com/markets/2065373/heron-therapeutics-hrtx-receives-news-sentiment-score-of-0-03.html.

About Heron Therapeutics

Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.

5 Day Chart for NASDAQ:HRTX

This story was originally published by WKRB News (http://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://www.wkrb13.com/markets/2065373/heron-therapeutics-hrtx-receives-news-sentiment-score-of-0-03.html

Receive News & Ratings for Heron Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.

 


Leave a Reply

 
© 2006-2017 WKRB News.